Harrington M A, Sleight A J, Pitha J, Peroutka S J
Department of Neurology, Stanford University School of Medicine, CA 94305.
Eur J Pharmacol. 1991 Feb 26;194(1):83-90. doi: 10.1016/0014-2999(91)90127-c.
A structure-activity analysis was used to identify selective 5-HT1A versus 5-HT1D receptor agents. An analysis of published data identified 13 drugs which display nanomolar affinity for the 5-HT1A receptor and that have been analyzed at 5-HT1D receptor binding sites. Four agents display greater than or equal to 100-fold selectivity for the 5-HT1A receptor. Two structural features were identified which hypothetically result in selectivity for 5-HT1A versus 5-HT1D binding sites. The linkage of an indole ring to a basic nitrogen atom via the 4 position on the indole ring or the absence of an indole ring are two features which lower the affinity for the 5-HT1D receptor, but do not necessarily lower the affinity for the 5-HT1A receptor. A series of 7 agents (5 indoles, 2 quinolines) was identified which met these hypothetical selectivity criteria. These compounds were then analyzed in radioligand binding studies. These 7 agents display affinities of 1.3-170 nM for the 5-HT1A receptor binding site, and 1,800-13,000 nM for the 5-HT1D receptor binding site. All 7 agents display greater than or equal to 47-fold selectivity for the 5-HT1A versus 5-HT1D site and 4 of the agents are greater than 100-fold selective. Compound No. 1 (N,N'-bis[3-(4-indolyloxy)-2-hydroxypropyl]-(Z)-1,8-diamino-p-meth ane) and compound No. 2 (N8-[3-(4-indolyloxy)-2-hydroxypropyl]-N1-(propioloyl)-(Z)-1 ,8-diamino-p-methane) are the most selective agents yet described for 5-HT1A versus 5-HT1D receptor binding sites.(ABSTRACT TRUNCATED AT 250 WORDS)
采用结构-活性分析来鉴定对5-HT1A受体与5-HT1D受体具有选择性的药物。对已发表数据的分析确定了13种对5-HT1A受体具有纳摩尔亲和力且已在5-HT1D受体结合位点进行分析的药物。4种药物对5-HT1A受体表现出大于或等于100倍的选择性。确定了两个结构特征,据推测这两个特征导致对5-HT1A与5-HT1D结合位点具有选择性。吲哚环通过吲哚环上的4位与碱性氮原子相连或不存在吲哚环是两个降低对5-HT1D受体亲和力但不一定降低对5-HT1A受体亲和力的特征。鉴定出一系列7种药物(5种吲哚类、2种喹啉类)符合这些假设的选择性标准。然后在放射性配体结合研究中对这些化合物进行分析。这7种药物对5-HT1A受体结合位点的亲和力为1.3 - 170 nM,对5-HT1D受体结合位点的亲和力为1800 - 13000 nM。所有7种药物对5-HT1A与5-HT1D位点的选择性均大于或等于47倍,其中4种药物的选择性大于100倍。化合物1(N,N'-双[3-(4-吲哚氧基)-2-羟丙基]-(Z)-1,8-二氨基对甲苯)和化合物2(N8-[3-(4-吲哚氧基)-2-羟丙基]-N1-(丙炔酰基)-(Z)-1,8-二氨基对甲苯)是迄今所描述的对5-HT1A与5-HT1D受体结合位点选择性最高的药物。(摘要截短于250字)